Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Taysha Gene Therapies, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome"
08/14/2023 8-K Quarterly results
Docs: "Form of Pre-Funded Warrant to Purchase Common Stock",
"Form of Securities Purchase Agreement, by and among Taysha Gene Therapies, Inc. and the Purchasers",
"Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results",
"Taysha Gene Therapies Announces $150 Million Private Placement Financing"
08/04/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
07/31/2023 8-K Quarterly results
06/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/19/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26 th Annual Meeting"
05/15/2023 8-K Quarterly results
Docs: "Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update"
04/27/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
01/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook"
01/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/08/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update"
10/27/2022 8-K Quarterly results
10/25/2022 8-K Quarterly results
10/25/2022 8-K Quarterly results
09/09/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/11/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update"
06/21/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/31/2022 8-K Quarterly results
01/31/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy"
01/27/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of ß-Hexosaminidase A Enzyme Activity in Patients with GM2 Gangliosidosis"
11/10/2021 8-K Quarterly results
Docs: "Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
10/05/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Construct for CLN7 and a Grant Award to Batten Hope"
06/29/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Company presentation",
"Company presentation"
06/28/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Company presentation",
"Company presentation"
06/17/2021 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 17, 2021 Taysha Gene Therapies, Inc. Delaware 001-39536 84-3199512 3000 Pegasus Park Drive, Suite 1430 Dallas, Texas 75247 612-0000 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to ..."
05/11/2021 8-K Quarterly results
Docs: "Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update"
04/14/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Corporate presentation",
"Taysha Gene Therapies Announces New Data on Multiple Preclinical Programs and Upcoming R&D Day"
04/12/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 12, 2021 Taysha Gene Therapies, Inc. Delaware 001-39536 84-3199512 2280 Inwood Road Dallas, Texas 75235 612-0000 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under t...",
"Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease"
03/09/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 9, 2021 Taysha Gene Therapies, Inc. Delaware 001-39536 84-3199512 2280 Inwood Road Dallas, Texas 75235 612-0000 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under th...",
"Taysha Gene Therapies Announces Collaboration to Advance Next-Generation Mini-Gene Payloads for an AAV Gene Therapy for the Treatment of Neurodevelopmental Disorders"
03/03/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update"
02/01/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : February 1, 2021 Taysha Gene Therapies, Inc. Delaware 001-39536 84-3199512 2280 Inwood Road Dallas, Texas 75235 612-0000 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under...",
"Taysha Gene Therapies Highlights Strategic Priorities and Provides 2021 Business Outlook"
01/19/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy